Phillips R, Januszewicz W, Pilonis ND, et al. - A multicenter cohort study was conducted to ascertain the incidence and prevalence of neoplasia in Barrett's esophagus samples harboring indefinite for dysplasia (BE-IND). Researchers included patients with confirmed BE-IND from two academic centers with no prior evidence of dysplasia who had undergone endoscopic follow-up (FU) of ≥ 1 year. The researchers estimated the rate of progression to neoplasia and classified it as prevalent (progression < 1year of FU) and incident (progression ≥ 1 year of FU). To find risk factors for progression, they conducted multivariable regression adjusted for relevant clinical features. Between 1997 and 2017, they distinguished 465 patients diagnosed with BE-IND, of which 223 (48.0%) were excluded. After median 1.5 years, 184 (76.0%) of the remaining patients had no evidence of dysplasia during FU, 23 patients (9.5%) developed prevalent neoplasia, and 35 patients (14.5%) developed incident neoplasia. The results highlighted that clinicians should closely monitor individuals with BE-IND should, since nearly a quarter harbor or will soon develop dysplasia. Barrett's esophagus length was found to be a clinical predictor of neoplastic progression; nevertheless, more accurate molecular biomarkers for risk stratification are needed.